Type: Securities Fraud Investigation

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Biogen revealed on May 14, 2026, that the topline data from its Phase 2 CELIA study for diranersen  failed to meet its primary endpoints. Based on these facts, the Company’s shares fell about 6.4% on the same day.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Oculis claimed that its Phase 3 DIAMOND trials were “advancing as planned,” but then announced on May 29, 2026, that both DIAMOND trials failed to meet their primary endpoints. The Company added that based on these results, it would not pursue an FDA filing for its drug candidate.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Abivax’s Phase 3 ABTECT trial for obefazimod revealed rare malignancy cases as part of its results. Based on this news, shares of Abivax on June 2, 2026.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Medline is the subject of a report published by Reuters on June 3, 2026, titled: “Medline draws another US FDA warning in two months over quality lapses.” According to the article, “The Food and Drug Administration, in its letter dated May 28, said the company failed to thoroughly investigate microbial contamination incidents in finished drug products and also ​cited inadequate cleaning practices.”

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Robot Consulting Co., Ltd. (“Robot Consulting” or “the Company”) (NASDAQ: LAWR) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. TriSalus reported its Q1 financial results on May 12, 2026. The Company’s quarterly revenue declined year-over-year by more than 2.9%. The Company also cut its full year revenue guidance. The Company told investors, “the driver of this revision includes both the lower Q1 revenues from the commercial expansion and the delayed FDA clearance timing for TriNav Advance.” The Company added that FDA clearance for TriNav Advance “is now running approximately 5 months past the 30-day MDUFA review goal.”

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Ryan reported its Q4 and full year 2025 financial results on February 12, 2026. The Company’s organic revenue growth was sharply lower than in the prior-year period, and EBITDAC margin also fell. The Company said that the fourth quarter “marked an intensification of some of these property pricing trends” and that the Company saw “rate decreases of 25% to 35%, which was higher than what we were seeing earlier in the year.” Based on this news, shares of Ryan fell by almost 12.8% on the next day.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Doximity revealed its Q4 and full year 2026 financial results on May 13, 2026. The Company fell short of consensus estimates for full year revenue. The Company’s CEO warned that increased investment in AI will “weigh on near-term margins.” Based on this news, shares of Doximity fell by 23% on the next day.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Verra revealed that Avis Budget Group delivered a notice terminating its commercial services agreement, which resulted in the Company reducing its 2026 guidance. The Company had previously assumed a renewal of the agreement as part of its outlook and expected resolution with Avis Budget in the first half of the year.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Photronics reported its Q2 2026 financial results on May 28, 2026. The Company reported a year over year decline in revenue and declining operating margins. The Company explained, “in the near term, certain design releases have been delayed due to elevated fab utilization rates, which are extending new product launch timelines, memory supply constraints and related cost pressures for OEMs, and geopolitical uncertainty.” Based on this news, shares of Photronics fell by 36.4% on the same day.